Structure Therapeutics Inc.
GPCR
$54.51
-$0.19-0.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.57M | 22.87M | 17.57M | 14.80M | 15.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -100.00M | -- | -- |
| Total Operating Expenses | 118.63M | 89.38M | -13.74M | 73.79M | 70.45M |
| Operating Income | -118.63M | -89.38M | 13.74M | -73.79M | -70.45M |
| Income Before Tax | -105.93M | -75.78M | 33.17M | -65.60M | -61.52M |
| Income Tax Expenses | 234.00K | 190.00K | 170.00K | 108.00K | 139.00K |
| Earnings from Continuing Operations | -106.16M | -75.97M | 33.00M | -65.71M | -61.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -106.16M | -75.97M | 33.00M | -65.71M | -61.66M |
| EBIT | -118.63M | -89.38M | 13.74M | -73.79M | -70.45M |
| EBITDA | -118.06M | -88.79M | 14.47M | -73.41M | -70.16M |
| EPS Basic | -4.38 | -3.15 | 1.56 | -3.37 | -3.21 |
| Normalized Basic EPS | -0.91 | -0.65 | 0.35 | -0.70 | -0.67 |
| EPS Diluted | -4.38 | -3.15 | 1.56 | -3.37 | -3.21 |
| Normalized Diluted EPS | -0.91 | -0.65 | 0.35 | -0.70 | -0.67 |
| Average Basic Shares Outstanding | 72.65M | 72.44M | 63.39M | 58.49M | 57.55M |
| Average Diluted Shares Outstanding | 24.22M | 24.15M | 21.13M | 19.50M | 19.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |